Andere Sprachen Annovis Bio, Inc.

Aktien

A2PNH2

US03615A1088

ANVS

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 26.04.2024			% 5 Tage	% 1. Jan.
18,01 ^USD	+32,43 %		+79,03 %	-3,69 %

01.04.	Annovis kündigt Veröffentlichung an, die das Verständnis des Wirkmechanismus von Buntanetap beim Menschen unterstützt	CI
29.03.	Annovis Bio, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Annovis Bio : Material Agreement - Form 8-K	26.04.
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	02.04.
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	01.04.
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	01.04.
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Top Midday Gainers	20.03.
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20.03.
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20.03.
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	20.03.
Annovis Bio : Material Event - Form 8-K	20.03.
Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding	15.03.
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	15.03.
North American Morning Briefing : Fed's Preferred -2-	29.02.
Annovis Bio Shares Fall After Downgrade From Brookline Capital	28.02.
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	27.02.
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	27.02.
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE	15.02.
Annovis Bio Completes Phase 2 Study of Alzheimer's Treatment Candidate	14.02.
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease	14.02.
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	14.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Annovis Bio, Inc.

Aktien

A2PNH2

US03615A1088

ANVS

Andere Sprachen

Filter